Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICVAX in clinically stable HIV patients under ART
NCT06253533Phase 1Completed
- Sponsor
- Immuno Cure
- Start
- Feb 2023
- Primary completion
- Sep 2024
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ICVAX in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Immuno Cure. Primary endpoint: Incidence of adverse events at week 36. Started Feb 2023; status: completed.
02
Drugs
ICVAX
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06253533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253533.